Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 158.00 -7 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $165.00 | 52 Week High | $109.10 | |||
| Open | $163.10 | 52 Week Low | $31.38 | |||
| Day High | $163.90 | P/E | N/A | |||
| Day Low | $156.00 | EPS | $-1.45 | |||
| Volume | 4,763,520 | |||||
